Is a randomised controlled trial of take home naloxone distributed in emergency settings likely to be feasible and acceptable? Findings from a UK qualitative study exploring perspectives of people who use opioids and emergency services staff
-
Published:2024-04-29
Issue:1
Volume:24
Page:
-
ISSN:1471-227X
-
Container-title:BMC Emergency Medicine
-
language:en
-
Short-container-title:BMC Emerg Med
Author:
Sampson FC,Hughes J,Long J,Buykx P,Goodacre SW,Snooks H,Edwards A,Evans Bridie,Jones Jenna,Moore Chris,Johnston Sasha
Abstract
Abstract
Objective
Distribution of take-home naloxone (THN) by emergency services may increase access to THN and reduce deaths and morbidity from opioid overdose. As part of a feasibility study for a randomised controlled trial (RCT) of distribution of THN kits and education within ambulance services and Emergency Departments (EDs), we used qualitative methods to explore key stakeholders’ perceptions of feasibility and acceptability of delivering the trial.
Methods
We undertook semi-structured interviews and focus groups with 26 people who use opioids and with 20 paramedics and ED staff from two intervention sites between 2019 and 2021. Interviews and focus groups were recorded, transcribed verbatim and analysed using Framework Analysis.
Results
People using opioids reported high awareness of overdose management, including personal experience of THN use. Staff perceived emergency service provision of THN as a low-cost, low-risk intervention with potential to reduce mortality, morbidity and health service use. Staff understood the trial aims and considered it compatible with their work. All participants supported widening access to THN but reported limited trial recruitment opportunities partly due to difficulties in consenting patients during overdose. Procedural problems, restrictive recruitment protocols, limited staff buy-in and patients already owning THN limited trial recruitment. Determining trial effectiveness was challenging due to high levels of alternative community provision of THN.
Conclusions
Distribution of THN in emergency settings was considered feasible and acceptable for stakeholders but an RCT to establish the effectiveness of THN delivery is unlikely to generate further useful evidence due to difficulties in recruiting patients and assessing benefits.
Funder
National Institute for Health and Care Research
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Hedegaard H, Warner M, Minino AM. Drug overdose deaths in the United States, 1999–2015. NCHS Data Brief. 2017;273:1–8.
2. ONS, Office of National Statistics. 2021, 2018. Deaths related to drug poisoning in England and Wales: 2018.
3. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2021: Trends and Developments, Publications Office of the European Union, Luxembourg. 2021. European Drug Report 2021 | www.emcdda.europa.eu.
4. WHO, Naloxone. A take-home antidote to drug overdose that saves lives [Internet]. WHO. http://www.who.int/features/2014/naloxone/en/.https://www.who.int/publications/i/item/9789241548816.
5. Darke S, Ross J, Teesson M, Lynskey M. Health service utilization and benzodiazepine use among heroin users: findings from the Australian treatment outcome study (ATOS). Addiction. 2003;98(8):1129–35.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献